跳至主要内容
临床试验/NCT05995808
NCT05995808尚未招募不适用

Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests

Sohag University0 个研究点目标入组 30 人开始时间: 2023年9月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
30
主要终点
Cycline D1 expression in bone marrow biopsy of multiple myeloma patient

研究概览

简要总结

Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and takes the second place after non-Hodgkin lymphoma .

There are some serological and clinical criteria that help to detect the stage of MM and predict the patients' prognosis. These criteria include the level of M protein, calcium, haemoglobin, albumin, creatinine, β2-microglobulin and glomerular filtration rate (GFR).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients older than 18 year with newly diagnosed MM.
  • Approval to sign an informed written consent.

排除标准

  • Patient younger than 18 years. 2.Refusal to sign an informed written consent.

结局指标

主要结局

Cycline D1 expression in bone marrow biopsy of multiple myeloma patient

时间窗: 1 year

Cycline D1 expression in bone marrow biopsy of multiple myeloma patient

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fainan Khaled Ahmed

clinical pathology specialist

Sohag University

相似试验